(Q34468570)

2 August 2017

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

4

Claudia Schoch

1 reference

2 August 2017

Martin Ruthardt

12

1 reference

ORCID Public Data File 2021

author name string

Gesine Bug

1

1 reference

2 August 2017

Markus Ritter

2

1 reference

2 August 2017

Barbara Wassmann

3

1 reference

2 August 2017

Thorsten Heinzel

5

1 reference

2 August 2017

Kerstin Schwarz

6

1 reference

2 August 2017

Annette Romanski

7

1 reference

2 August 2017

Oliver H Kramer

8

1 reference

2 August 2017

Manuela Kampfmann

9

1 reference

2 August 2017

Dieter Hoelzer

10

1 reference

2 August 2017

Andreas Neubauer

11

1 reference

2 August 2017

Oliver G Ottmann

13

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

2 August 2017

1 reference

2 August 2017

104

1 reference

2 August 2017

2717-2725

1 reference

2 August 2017

12

1 reference

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

2 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

What's up and down with histone deacetylation and transcription?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Mechanisms of action of valproate: a commentatory

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Pro- and anticoagulatory factors under sodium valproate-therapy in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21589

7 January 2021

Identifiers

DOI

10.1002/CNCR.21589

1 reference

2 August 2017

1 reference